Share-based Payment Arrangement, Expense in USD of EAGLE PHARMACEUTICALS, INC. from 2012 to Q2 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
EAGLE PHARMACEUTICALS, INC. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q2 2023.
  • EAGLE PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2023 was $4,192,000, a 6.8% decline year-over-year.
  • EAGLE PHARMACEUTICALS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2023 was $16,487,000, a 6.1% decline year-over-year.
  • EAGLE PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $16,451,000, a 16% decline from 2021.
  • EAGLE PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2021 was $19,555,000, a 21% decline from 2020.
  • EAGLE PHARMACEUTICALS, INC. annual Share-based Payment Arrangement, Expense for 2020 was $24,756,000, a 13% increase from 2019.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

EAGLE PHARMACEUTICALS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2023 $16,487,000 $4,192,000 -$308,000 -6.8% 01 Apr 2023 30 Jun 2023 10-Q/A 09 Aug 2023 2023 Q2
Q1 2023 $16,795,000 $4,639,000 +$344,000 +8% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $16,451,000 $4,119,000 -$563,000 -12% 01 Oct 2022 31 Dec 2022 10-K 23 Mar 2023 2022 FY
Q3 2022 $17,014,000 $3,537,000 -$547,000 -13% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2022 2022 Q3
Q2 2022 $17,561,000 $4,500,000 +$219,000 +5.1% 01 Apr 2022 30 Jun 2022 10-Q/A 09 Aug 2023 2023 Q2
Q1 2022 $17,342,000 $4,295,000 -$2,213,000 -34% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $19,555,000 $4,682,000 -$1,639,000 -26% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $21,194,000 $4,084,000 -$638,000 -14% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $21,832,000 $4,281,000 -$1,960,000 -31% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $23,792,000 $6,508,000 -$964,000 -13% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $24,756,000 $6,321,000 +$1,138,000 +22% 01 Oct 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
Q3 2020 $23,618,000 $4,722,000 -$929,000 -16% 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $24,547,000 $6,241,000 +$859,000 +16% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $23,688,000 $7,472,000 +$1,690,000 +29% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $21,998,000 $5,183,000 +$613,000 +13% 01 Oct 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
Q3 2019 $21,385,000 $5,651,000 +$1,179,000 +26% 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $20,206,000 $5,382,000 +$647,000 +14% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $19,559,000 $5,782,000 +$477,000 +9% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $19,082,000 $4,570,000 +$759,000 +20% 01 Oct 2018 31 Dec 2018 10-K 05 Mar 2021 2020 FY
Q3 2018 $18,323,000 $4,472,000 +$744,000 +20% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $17,579,000 $4,735,000 +$1,038,000 +28% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $16,541,000 $5,305,000 +$1,112,000 +27% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $15,429,000 $3,811,000 +$1,582,000 +71% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $13,847,000 $3,728,000 +$1,478,000 +66% 01 Jul 2017 30 Sep 2017 10-Q 01 Nov 2018 2018 Q3
Q2 2017 $12,369,000 $3,697,000 +$1,277,000 +53% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $11,092,000 $4,193,000 +$1,324,000 +46% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $9,768,000 $2,229,000 +$1,120,000 +101% 01 Oct 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
Q3 2016 $8,648,000 $2,250,000 +$901,000 +67% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $7,747,000 $2,420,000 +$1,211,000 +100% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $6,536,000 $2,869,000 +$2,485,000 +647% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $4,051,000 $1,109,000 +$825,000 +290% 01 Oct 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
Q3 2015 $3,226,000 $1,349,000 +$1,125,000 +502% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2016 2016 Q3
Q2 2015 $2,101,000 $1,209,000 +$1,045,000 +637% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $1,056,000 $384,000 +$100,000 +35% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q4 2014 $956,000 $284,000 +$206,000 +264% 01 Oct 2014 31 Dec 2014 10-K 15 Mar 2017 2016 FY
Q3 2014 $750,000 $224,000 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $164,000 +$35,687 +28% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $284,000 +$186,787 +192% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q1
Q4 2013 $78,000 01 Oct 2013 31 Dec 2013 10-QT 17 Feb 2015 2014 Q4
Q2 2013 $128,313 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q3
Q1 2013 $97,213 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014 2014 Q2

EAGLE PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2022 $16,451,000 -$3,104,000 -16% 01 Jan 2022 31 Dec 2022 10-K 23 Mar 2023 2022 FY
2021 $19,555,000 -$5,201,000 -21% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $24,756,000 +$2,758,000 +13% 01 Jan 2020 31 Dec 2020 10-K 23 Mar 2023 2022 FY
2019 $21,998,000 +$2,916,000 +15% 01 Jan 2019 31 Dec 2019 10-K 08 Mar 2022 2021 FY
2018 $19,082,000 +$3,653,000 +24% 01 Jan 2018 31 Dec 2018 10-K 05 Mar 2021 2020 FY
2017 $15,429,000 +$5,661,000 +58% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $9,768,000 +$5,717,000 +141% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $4,051,000 +$3,445,000 +568% 01 Jan 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
2014 $606,000 +$289,000 +91% 01 Oct 2013 30 Sep 2014 10-K 15 Mar 2017 2016 FY
2013 $317,000 -$85,000 -21% 01 Oct 2012 30 Sep 2013 10-K 29 Feb 2016 2015 FY
2012 $402,000 01 Oct 2011 30 Sep 2012 10-K 22 Dec 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.